Cormorant Global Healthcare Master Fund, LP, Director at Verve Therapeutics, Inc. (VERV), bought 984,224 shares at $19.00 ($5.2M) on 2021-06-21, disclosed to the SEC on 2021-06-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 709,224 | $0 | 0.0% |
| 2 | $19.00 | 275,000 | $5.2M | 100.0% |
| Total | $5.31 avg | 984,224 | $5.2M | 100% |
| Filing → |
| DRUG | BUY | 2024-10-17 | $6.4M | — | Filing → |
| CRBP | BUY | 2024-09-24 | $14.0M | — | Filing → |
| EYPT | BUY | 2024-04-22 | $21.0M | — | Filing → |